Cepheid, a Danaher company, today announced it has donated an initial shipment of Xpert® Hemorrhagic Fever panel tests to support the diagnostic response to the Ebola Bundibugyo (BDBV) outbreak in the ...

Cepheid, a Danaher company and a leader in molecular diagnostics, today announced that it has received Emergency Use Listing ...

SUNNYVALE, Calif., June 9, 2020 /PRNewswire/ -- Cepheid today announced the development of a next-generation test to assist global efforts in the fight against the spread of COVID-19 during the ...

Sherlock Biosciences has teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech for new tests on the latter’s automated laboratory systems. The collaboration will focus on ...

SUNNYVALE, Calif., Dec. 8, 2022 /PRNewswire/ -- Currently circulating mutant strains of influenza highlight the need for multi-target diagnostic tests. Two recently identified mutations in the matrix ...

Cepheid has received emergency authorization from the Food and Drug Administration to use its rapid molecular test for point-of-care patients that can detect coronavirus in 45 minutes. This is the ...

SUNNYVALE, Calif. , Feb. 18, 2026 /PRNewswire/ -- Cepheid today announced that it has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators ...

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Cepheid, a Danaher (NYSE:DHR) subsidiary, is donating and deploying Xpert Hemorrhagic Fever ...

(Reuters) - Molecular diagnostics company Cepheid said it received a grant of up to $3.3 million, co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation, to develop ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...